Mackenzie Financial Corp Taysha Gene Therapies, Inc. Transaction History
Mackenzie Financial Corp
- $71.6 Billion
- Q2 2025
A detailed history of Mackenzie Financial Corp transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 11,214 shares of TSHA stock, worth $56,070. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,214
Previous 10,000
12.14%
Holding current value
$56,070
Previous $13,000
92.31%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
155Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$125 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$118 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$109 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$84.3 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$63 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $242M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...